GlassScriptPhysician profile
Luis R Forti
NPI 1205923505
$7,970.35
in general payments reported to CMS, 2019-2025
24 companies · $598 in 2025
The $598 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $1,106 · 2021: $1,721 · 2022: $1,354 · 2023: $955 · 2024: $1,109 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,661.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,068.29 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,318.40 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $570.73 | 2019-2023 | Xarelto, Invokana |
| Novo Nordisk INC | $523.05 | 2020-2025 | Ozempic, Rybelsus |
| Eli Lilly Export S.A. Puerto Rico Branch | $469.60 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Bayer Puerto Rico INC. | $382.09 | 2023-2025 | Kerendia |
| Bayer Healthcare Pharmaceuticals INC. | $319.22 | 2021-2024 | |
| Amgen INC. | $218.56 | 2020-2025 | Repatha, Prolia, Evenity |
| Merck Sharp & Dohme LLC | $208.04 | 2019-2024 | Janumet, Januvia, Segluromet |
| Sanofi-Aventis U.S. LLC | $173.55 | 2021-2022 | |
| Pbg Puerto Rico LLC | $148.84 | 2019-2021 | |
| Glaxosmithkline, LLC. | $92.50 | 2019-2024 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $88.85 | 2019-2022 | |
| Dexcom, INC. | $81.97 | 2021-2024 | Dexcom G6 Transmitter |
| Mannkind Corporation | $59.40 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.45 | 2023-2024 | |
| Abbott Laboratories | $42.82 | 2021-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $28.13 | 2022 | |
| Abbvie INC. | $25.00 | 2023 | |
| Exact Sciences Corporation | $25.00 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $21.27 | 2020 | |
| Boston Scientific Corporation | $20.33 | 2025 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $20.30 | 2019 | |
| Pfizer Pharmaceuticals LLC | $18.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Forti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.